Introduction {#sec0005}
============

In December 2019, a novel coronavirus, the severe acute respiratory syndrome coronavirus-2 (SARS- CoV-2) which causes a human disease named coronavirus disease (COVID-19) was identified in the pneumonia outbreaks in Wuhan, China, in December 2019 ([@bib0025]). It is currently expanding rapidly to several countries all-around the word, on February 21 the first person-to-person transmission in Italy was reported ([@bib0115]). Here, we report a case of SARS-CoV-2 and Influenza A co-infection and a mini-review of the literature.

Case presentation {#sec0010}
=================

A 56 year-old male general surgeon was admitted to the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, Italy, on March 6, 2020. He was a smoker, within the overweight range (29-body mass index), with a history of two episodes of acute myocardial infarction treated with coronary angioplasty and stenting, For 4 days, he had been complaining of fever, diarrhea and asthenia after winter ski week in Northern Italy. Two days after the onset of symptoms, a nasopharyngeal swab was positive for SARS-CoV-2 (genes E and S) and Influenza A. On March 6, a chest computed tomography (CT) scan revealed bilateral and multiples peripheral ground glass opacities. Blood tests showed lymphopenia (lymphocyte and monocyte cell count: 0.67 and 0.09 × 109/L respectively), C- reactive protein and serum fibrinogen levels were increased (43.3 g/L and 7980 g/L respectively). An arterial oxygen tension (PaO2)/fractional inspired oxygen (FiO2) P/F Ratio was 320. Oral oseltamivir (75 mg twice per day for 5 days) and lopinavir/ritonavir (400/100 mg twice per days for 14 days) were started together with antibiotic therapy (intravenous ceftriaxone 2 gr and oral azithromycin 500 mg per day) and intravenous methylprednisolone (40 mg twice daily for 5 days with tapered discontinuation). On day eight of hospitalization, he developed respiratory failure (P/F Ratio dropped to 202) and a second chest CT scan showed a worsening of the bilateral ground-glass opacities with fibrotic consolidation in both lower pulmonary lobes ([Figure 1](#fig0005){ref-type="fig"} a). At that time, nasopharyngeal swabs were positive for SARS-CoV-2, only. The patient was transferred to the Intensive Care Unit (ICU) and non-invasive ventilation through continuous positive airway pressure (C-PAP) mask was started with positive end-expiratory pressure (PEEP) 7.5 mmHg and FiO2 40%. After three days, he was re-admitted to the High Isolation Unit and discharged in good clinical conditions with persistently negative nasopharyngeal swabs. A SARS-CoV-2 serology by an in house indirect immunofluorescence assay (IgA 1:1280, IgM 1:320 and IgG 1:80) was positive ([@bib0040]). During the following week, low-grade fever re-occurred with nocturnal sweats, a third CT scan showed a reduction of the ground glass areas with residual interstitial damage ([Figure 1](#fig0005){ref-type="fig"}b) and a further nasopharyngeal swab was negative. Symptoms healed spontaneously few days later.Figure 1Chest computer tomography scan at patient's worsening and recovery.(a) Bilateral ground-glass opacities with fibrotic consolidation in both lower pulmonary lobes (b) reduction of the ground glass areas with residual interstitial damage.Figure 1

Discussion {#sec0015}
==========

Previous cases of viral pneumonia SARS-CoV-2 and influenza coinfection have been reported in literature. During the new coronavirus epidemic, a total number of 37 cases were described. [Table 1](#tbl0005){ref-type="table"} summarizes the characteristics of the coinfected patients. Fourteen cases belonged to epidemiological studies and clinical data were not available. All patients had a similar clinical presentation (fever, cough and shortness of breath) and 9 of them (9/37, 24.3%) presented a progressive worsening with ARDS. Furthermore, six patients needed ICU monitoring and were subsequently discharged in good clinical conditions with the exception of three patients who died.Table 1Clinical characteristics of SARS-CoV-2 and influenza coinfection, COVID-19 epidemic.Table 1ReferencesSexAgeComorbiditiesCoinfectionOseltamivirAntiviralsGlucorticoidsARDSICUNIVIMVOutcome[@bib0005]F78Dyslipidemia, hypothyroidismInfluenza AYesNoNoNoNoNoNoSurvived[@bib0010]NANANAInfluenza A and RSVNANANANANANANANA[@bib0045]M53ERSDInfluenza AYesYesNAYesYesNoYesSurvivedM78T2DMInfluenza AYesYesNAYesYesNoYesSurvivedM56T2DMInfluenza A and BNoNoNANoNoNoNoSurvivedF81ERSDInfluenza BYesYesNAYesYesNoYesSurvived[@bib0050]NA36NAInfluenza BNANANANANANANANA[@bib0055]F47NoneInfluenza AYesYesYesNoNoNoNoSurvivedM50Hypertension, cancerInfluenza AYesYesYesYesNoYesNoSurvivedF66Hypertension, CVD, HBVInfluenza BYesYesNoNoNoNoNoSurvivedM39HBVInfluenza BYesYesYesNoNoNoNoSurvivedF49NoneInfluenza AYesYesNoNoNoNoNoSurvived[@bib0060]NA\<17NAInfluenza ANANANANANANANANA[@bib0065]F78NAInfluenza AYesYesNAYesNANANADeadM75NAInfluenza AYesYesNAYesNANANADead[@bib0070]F74Hypertension, CVDInfluenza AYesYesNoNoNoNoNoSurvivedM40NoneInfluenza AYesYesNoNoNoNoNoSurvivedM64NoneInfluenza AYesYesNoNoNoNoNoSurvivedM50NoneInfluenza AYesYesNoNoNoNoNoSurvived[@bib0075]NANANAInfluenza ANANANANANANANANA[@bib0085]M57Hypertension, T2DM, CVD, AICDInfluenza AYesYesNoNoNoNoNoSurvivedF35Sickle cell traitInfluenza AYesYesNoNoNoNoNoSurvivedF68T2DM, hypertension, GERDInfluenza BYesYesNAYesYesNoYesDead[@bib0080]F66T2DM, CVD, hypertension, CKDInfluenza AYesYesNAYesYesNoYesSurvived[@bib0100]NANANAInfluenza ANANANANANANANANA[@bib0105]M61NoneInfluenza AYesNoNoNoNoNoNoSurvived[@bib0110]NANANAInfluenza ANANANANANANANANA[@bib0125]NA4 monthsNoneInfluenza AYesNoNoNoNoNoNoSurvived[@bib0135]NA\<17NAMP, Influenza A&B, RSVNANANANANANANANA[@bib0140]M69NoneInfluenza AYesNANAYesYesNoYesSurvived[@bib0145]NANANA2 pts Influenza ANANANANANANANANA5 pts Influenza B[^2]

Even during a pandemic scenario, several respiratory pathogens should be considered in the diagnostic algorithm, for an early etiological identification and appropriate treatment. SARS-CoV-2 and influenza viruses share common route of transmission, same season occurrence and overlapping clinical features ([@bib0090], [@bib0030]). Indeed, SARS-CoV-2 exhibits prevalent human-to-human transmission through close contact with an estimated R0 of 3.28 and a median of 2.79 with IQR of 1.6 ([@bib0095]).

Respiratory symptoms are always the initial manifestations of both SARS-CoV-2 and influenza infections which could progress towards ARDS. Recently, ground-glass opacities and a higher median PaO2/FIO2 (198.2 vs 107.0) were observed in COVID-19-induced ARDS rather than H1N1 patients ([@bib0120]).

Nevertheless, a timely identification of the two co-infections is needed in relation to difference in treatments and prognosis. Antiviral therapy is currently available for influenza infection (i.e. oseltamivir, zanamivir, and peramivir) while experimental off-label drugs (i.e. lopinavir/ritonavir, chloroquine, and hydroxychloroquine) have been commonly used in COVID-19 treatment. In particular, the boosted protease inhibitor lopinavir/ritonavir has been previously associated with significantly fewer adverse clinical outcomes for the treatment of SARS and furthermore, in association with the Interferon Beta-1b, it has been demonstrated to be beneficial in animal studies against the Middle East Respiratory Syndrome ([@bib0035], [@bib0020]). Considering the severity of the clinical picture and the prompt availability of lopinavir/ritonavir in our Institute, clinicians opted for this treatment although the antiviral effects remain to be determined ([@bib0015]).

Despite a recent report on beneficial effect of steroids treatment in COVID-19 patients who develop ARDS, its routinely use remains controversial with lack of an accurate assessment of the harm/benefit balance ([@bib0130]).

The epidemiological situation in Italy in February 2020 and the recommendations in use at that time allowed a timely identification of our patient with a prompt hospitalization and subsequent diagnostic investigations. Therefore, the early antiviral treatments of both influenza and SARS-CoV-2, together with a brief steroid course and oxygen supplementation, had an impact on the patient's outcome avoiding the progressive worsening and the evolution towards the severe ARDS phase. In conclusion, even in epidemic setting, the early and prompt identification of concurrent respiratory pathogens is important in order to improve etiological diagnosis, preventive measures and patients' clinical management and outcome. Further studies are needed to better understand the pathogenic role of viral coinfections in respiratory diseases.
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